Please ensure Javascript is enabled for purposes of website accessibility

Could This Alzheimer’s Disease Drug Really Be Worth $20 Billion?

By George Budwell – Sep 19, 2016 at 1:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This moonshot is exciting -- but it isn't a compelling reason to buy Biogen's shares right now.

Biogen's (BIIB 0.56%) plaque-busting Alzheimer's disease (AD) drug candidate, aducanumab, could represent a jaw-dropping $20 billion peak commercial opportunity for the company and its shareholders. Putting this monstrous figure into context, this experimental medicine has the potential to even surpass AbbVie's anti-inflammatory drug, Humira, which is on track to generate upwards of $16 billion in global sales by 2018 and is currently the world's best-selling drug. 

Image source: Getty Images.

Although this $20 billion peak sales figure may sound ridiculous at first, there are some solid reasons to believe that it's not completely far-fetched. First off, there are presently no disease-modifying treatments available for this devastating neurodegenerative disorder, reflecting the astronomically high failure rate of experimental AD drugs. Second, the incidence rates of AD have been growing by leaps and bounds largely due to an aging global population.

That's why J.P. Morgan's analysts, among others, have suggested that any disease-modifying AD drug that somehow makes it all the way to market would quickly rack up over $10 billion in sales. And without a major competitor to divvy up the market, that figure could balloon to over $20 billion by 2030. 

Sounds good, but should investors believe the hype?

Biogen's AD drug candidate belongs to a class of experimental therapies designed to reduce beta-amyloid plaque levels within the brain, which theoretically should slow disease progression -- that is, if these plaques really are the root cause of AD. Unfortunately, the clinical data thus far have revealed a perplexing disconnect between plaque levels and underlying disease pathology. 

As an example, Eli Lilly's (LLY 0.98%) solanezumab -- a drug not unlike aducanumab -- failed to show an improvement in cognitive ability in patients with mild to moderate Alzheimer's disease across two large late-stage studies. Making matters worse, several other anti-amyloid therapies have also failed to improve cognitive ability and/or daily function in AD patients, casting doubt on the amyloid plaque hypothesis. 

More broadly, the picture that's slowly emerging is that the complex biology underpinning AD may simply make it impossible to develop a "one-size-fits-all" type of medication. Anti-amyloid therapies -- like those being developed by Biogen and Lilly -- may ultimately end up being used as part of a combination therapy as a result. 

Given the disappointing clinical history of anti-amyloid therapies and the fact that researchers still don't fully understand the underlying causes of AD, investors should probably view this $20 billion peak sales estimate purely as a blue sky scenario. In other words, it's not impossible, but it's certainly not probable. 

What's next?

Biogen is in the midst of carrying out two phase 3 trials for aducanumab, dubbed "Engage" and "Emerge," respectively. Taken together, these two trials are expected to enroll 2,700 patients worldwide, which should provide ample power to assess the drug's impact on cognitive ability and the daily lives of AD patients.

Having said that, these trials won't produce top-line data until at least mid-2020. By then, Lilly's presumed last attempt at resurrecting solanezumab will have come and gone, perhaps providing a preview of aducanumab's fate in the process. But if history is any guide, aducanumab probably won't fare any better than solanezumab did in its first late-stage trials, meaning that this moonshot effort shouldn't be the primary reason for investing in Biogen -- despite its awe-inspiring commercial potential. 

George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Biogen. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Stock Quote
$305.15 (0.56%) $1.70
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$365.25 (0.98%) $3.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.